To keep up with de­mand, Sor­ren­to ac­quires ma­jor­i­ty own­er­ship in Covid-19 test man­u­fac­tur­er

In a move that the com­pa­ny hopes will up its abil­i­ty to re­spond to de­mand for its Covid-19 tests, Sor­ren­to Ther­a­peu­tics has ac­quired a ma­jor­i­ty own­er­ship in a Chi­nese di­ag­nos­tics man­u­fac­tur­er.

Sor­ren­to Ther­a­peu­tics will use Zhengzhou For­tune Bio­science to man­u­fac­ture Co­v­is­tix, its rapid anti­gen sec­tion test for Covid-19 and its vari­ants. The tests have been ap­proved for emer­gency use and is on the mar­ket in Brazil and Mex­i­co. The com­pa­ny now has a ma­jor­i­ty own­er­ship, with the op­tion to ac­quire 100% of the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER